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Monica Tadros, Pharm.D., BCPS; Guenther Koehne, M.D., Ph.D.; Talia Zahra, M.D.; Moe Shwin, Pharm.D., BCOP;
Nicholas Chow, Pharm.D., BCOP; Jessica Unzaga, Pharm.D., BCPS, BCOP
Miami Cancer Institute, Baptist Health South Florida, Miami, FL

Introduction

Results

• Acute myeloid leukemia (AML) is characterized by proliferation of
immature myeloid cells in the bone marrow and primarily affects
older adults (median age of diagnosis of 69 years)1

Regimens

• Guideline-based treatment options for AML depend on patients’ age,
performance status, and adverse features such as unfavorable
cytogenetics or molecular markers, and comorbidities1
• Response and tolerability to standard AML therapy [7 days of
cytarabine plus 3 days of an anthracycline (7+3)] is reduced in elderly
patients; alternative treatment options include monotherapy with
hypomethylating agents (HMA) such as azacitidine or decitabine,
however, use of these agents alone are associated with poorer
response rates 2
• Venetoclax, an oral BCL-2 inhibitor, is FDA approved in combination
with HMAs or low-dose cytarabine for the treatment of newlydiagnosed AML in adults 75 years or older, or patients with
comorbidities that preclude the use of intensive induction
chemotherapy3,4
• Venetoclax + HMAs has been associated with 61% complete
remission (CR)/ complete remission with incomplete count recovery
(CRi) rates in treatment-naïve older adults3,4
• Guidelines support the use of venetoclax in combination with HMAs
or low dose cytarabine for patients ages 60 and older with
unfavorable risk cytogenetics that are candidates for intensive
remission induction therapy1

Objective
Evaluate the outcomes of AML induction regimens in patients 60 years
or older with unfavorable risk cytogenetics that are candidates for
intensive remission induction therapy at a community hospital

Methods
• Design: Single-center, IRB-approved, retrospective chart review
• Evaluation period: February 1st, 2018 - August 1st, 2019
• Primary outcomes: Rate of complete morphologic remission +
complete morphologic remission with incomplete count recovery
(CR/CRi)*
• Secondary outcomes: Rate of induction failure*, relapse free survival
(RFS)*, time to CR/CRi, hospital length of stay (LOS), percentage of
patients who went on to receive transplant, grade 1-5 treatmentrelated toxicities**
• Inclusion criteria: Age 60 or older at start of treatment, admitted to
hospital oncology inpatient unit, confirmed AML diagnosis,
unfavorable risk cytogenetics
• Regimens studied: cytarabine/daunorubicin (7+3 reference group);
liposomal daunorubicin/cytarabine for therapy-related AML (CPX-351
reference group); venetoclax/decitabine (VEN+DEC); venetoclax/
azacitidine (VEN+AZA); venetoclax/low dose cytarabine (VEN+LoDAC)
• Exclusion criteria: Received prior therapy for AML
• Procedure: Patients identified using ICD 10 AML diagnosis codes;
Fischer’s exact test (categorical) and unpaired t test (continuous) used
to determine statistical significance at an alpha of 0.05
*Outcomes defined by International Working Group response criteria for AML
**Toxicities graded using National Cancer Institute Common Terminology Criteria for
Adverse Event [CTCAE] Version 5.0

Patient Characteristics

N=20

Mean age, years
Age 60-74
Age 75+

74
45% (9)
55% (11)

Gender, female

50% (10)

Diagnoses
• AML
• AML from MDS

50% (10)
50% (10)

Baseline ECOG status
• 0
• 1
• 2
• Not documented

25% (5)
25% (5)
5% (1)
45% (9)

15%

Discussion
Patient Characteristics
Mutations Found
45%

20%
15%

7+3 (n=9)
VEN+DEC (n=5)
VEN+LoDAC (n=0)

CPX-351 (n=3)
VEN+AZA (n=3)

TP53
RUNX1
ASXL1
GATA2
FLT3
IDH1/2
NPM1
DNMT3A
STAG2
Del (7q)
Del (5q)
Del (17p)
Complex karyotype

20% (4)
10%(2)
5% (1)
10% (2)
25% (5)
20% (4)
25% (5)
40% (8)
20%(4)
10% (2)
10% (2)
10% (2)
40% (8)

• 7+3 (n=9)

78% (7)

22% (2)

26

283

34

67% (6)

11% (1)

• CPX-351 (n=3)

67% (2)

33% (1)

32

530

40

33% (1)

0

Low Intensity (n=8)

63% (5)

37% (3)

23

223

26

63% (5)

0

• VEN+DEC (n=5)

60% (3)

40% (2)

25.5

184

29

60% (3)

0

• VEN+AZA (n=3)

67% (2)

33% (1)

23

357

17

67% (2)

0

Outcome

Median duration of thrombocytopenia
(days)
31
23
32
32
18
38

High intensity (n=12)
100% (12)
100% (12)
92% (11)
92% 11)
42% (5)
8% (1)
8% (1)

Low intensity (n=8)
88% (7)
88% (7)
75% (6)
88% (7)
25% (2)
0
0

High intensity (n=12)

Low Intensity (n=8)

P value

CR/CRi rates

75%

63%

0.0922 (NS)

Median RFS

272 days

223 days

0.1496 (NS)

100%

88%

0.0003

Grade 3/4 toxicities
FN = febrile neutropenia
NS = not significant

• 2 patients were lost to follow up
Limitations of study design:
• Single center study
• Retrospective study creates potential for selection bias

• Low volume of patients due to extensive inclusion/exclusion criteria
and inconsistent number of patients per treatment group prevents
meaningful comparison between individual groups

75% (9)

Treatment-related toxicities
Any-grade toxicities
Grade 3/4 toxicities
Grade 3 FN
Grade 4 thrombocytopenia
Grade 1/2 AST or ALT increase
Grade 1/2 SCr increase
Grade 3 cardiotoxicity

• Febrile neutropenia was the most commonly observed toxicity in all
groups followed by grade 4 thrombocytopenia

8% (1)

High Intensity (n=12)

Rate of
induction
failure
25% (3)

High Intensity (n=12)
• 7+3 (n=9)
• CPX-351 (n=3)
Low Intensity (n=8)
• VEN+DEC (n=5)
• VEN+AZA (n=3)

• Rate of CR/CRi in venetoclax + HMA study cohorts is similar to those
reported in studies

Received
transplant

Rate of
CR/CRi

Median duration of neutropenia
(days)
30
27
30
34
38
30

• Significantly less grade 3/4 toxicities noted in low intensity group
when compared to high intensity

• Lack of thorough documentation in the electronic medical record,
particularly as is relates to baseline ECOG status and determining if
toxicities were treatment-related or disease-related

Regimen

Regimen

Median time Median RFS Median Transplant
to CR/CRi
(days)
LOS (days) eligible
(days)
26
272
33
58% (7)

N=20

Observations:
• There was no statistically significant difference between the CR rates
and RFS of the high and low intensity groups

• Unable to assess adherence to oral therapies (venetoclax) and
determine effect of potential drug-drug interactions
• Provider utilization of decitabine 5-day vs. 10-day regimen not
standardized
• Short duration of follow up (ongoing)

Conclusion
In this review, CR rates among the different regimens recommended for
elderly AML patients were comparable, with more toxicities being
observed with the more intensive regimens containing anthracyclines.
Further larger studies are needed to be able to more accurately compare
the regimens in terms of efficacy and toxicity.
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